Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

Background: Guidelines on the management of Helicobacter pylori, which cover indications for management and treatment strategies, were produced in 2000. Aims: To update the guidelines at the European Helicobacter Study Group (EHSG) Third Maastricht Consensus Conference, with emphasis on the potential of H pylori eradication for the prevention of gastric cancer. Results: Eradication of H pylori infection is recommended in (a) patients with gastroduodenal diseases such as peptic ulcer disease and low grade gastric, mucosa associated lymphoid tissue (MALT) lymphoma; (b) patients with atrophic gastritis; (c) first degree relatives of patients with gastric cancer; (d) patients with unexplained iron deficiency anaemia; and (e) patients with chronic idiopathic thrombocytopenic purpura. Recurrent abdominal pain in children is not an indication for a “test and treat” strategy if other causes are excluded. Eradication of H pylori infection (a) does not cause gastro-oesophageal reflux disease (GORD) or exacerbate GORD, and (b) may prevent peptic ulcer in patients who are naïve users of non-steroidal anti-inflammatory drugs (NSAIDs). H pylori eradication is less effective than proton pump inhibitor (PPI) treatment in preventing ulcer recurrence in long term NSAID users. In primary care a test and treat strategy using a non-invasive test is recommended in adult patients with persistent dyspepsia under the age of 45. The urea breath test, stool antigen tests, and serological kits with a high accuracy are non-invasive tests which should be used for the diagnosis of H pylori infection. Triple therapy using a PPI with clarithromycin and amoxicillin or metronidazole given twice daily remains the recommended first choice treatment. Bismuth-containing quadruple therapy, if available, is also a first choice treatment option. Rescue treatment should be based on antimicrobial susceptibility. Conclusion: The global burden of gastric cancer is considerable but varies geographically. Eradication of H pylori infection has the potential to reduce the risk of gastric cancer development.

[1]  L. Herszényi.  [Eradication of Helicobacter pylori]. , 2003, Orvosi hetilap.

[2]  D. Graham,et al.  Atrophic Gastritis and Intestinal Metaplasia in Japan: Results of a Large Multicenter Study , 2001, Helicobacter.

[3]  J. Freston.  Management of Peptic Ulcers: Emerging Issues , 2000, World Journal of Surgery.

[4]  R. Spiller,et al.  The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. , 1999, Gastroenterology.

[5]  O. Cars,et al.  Variation in antibiotic use in the European Union , 2001, The Lancet.

[6]  D. Forman,et al.  Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. , 1997, Gut.

[7]  G. Porro,et al.  Stool Test with Polyclonal Antibodies for Monitoring Helicobacter pylori Eradication in Adults: A Critical Reappraisal , 2002, Scandinavian journal of gastroenterology.

[8]  T. Northfield,et al.  A randomized trial of endoscopy vs no endoscopy in the management of seronegative Helicobacter pylori dyspepsia , 1998, European journal of gastroenterology & hepatology.

[9]  M. Stolte,et al.  Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. , 1997, Gastroenterology.

[10]  L. Hansson,et al.  Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. , 2001, Gastroenterology.

[11]  M. Pollán,et al.  Stomach cancer and occupation in Sweden: 1971–89 , 2002, Occupational and environmental medicine.

[12]  R. Hoover,et al.  Cancer risk following pernicious anaemia. , 1989, British Journal of Cancer.

[13]  P. Malfertheiner,et al.  Noninvasive antigen-based assay for assessing Helicobacter pylori eradication: a European multicenter study , 2000, American Journal of Gastroenterology.

[14]  H. Brenner,et al.  Helicobacter pylori infection among offspring of patients with stomach cancer. , 2000, Gastroenterology.

[15]  A. Axon,et al.  Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. , 2001, Gastroenterology.

[16]  Z. Tulassay,et al.  One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease , 2001, European journal of gastroenterology & hepatology.

[17]  B. Gold,et al.  Helicobacter pylori infection in children: To test or not test...what is the eviedence? , 2000 .

[18]  N. Yeomans.  New data on healing of nonsteroidal anti-inflammatory drug-associated ulcers and erosions. Omeprazole NSAID Steering Committee. , 1998, The American journal of medicine.

[19]  C. Nigro,et al.  Helicobacter pylori and gastroesophageal reflux disease , 2008, World journal of surgical oncology.

[20]  R. Genta,et al.  Evaluation of a new urease reagent strip for detection of Helicobacter pylori in gastric biopsy specimens. , 1995, The American journal of gastroenterology.

[21]  D. Forman,et al.  An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews , 2003, American Journal of Gastroenterology.

[22]  D. Graham,et al.  Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors , 2003, American Journal of Gastroenterology.

[23]  E. van Marck,et al.  Autoimmune gastropathy in type 1 diabetic patients with parietal cell antibodies: histological and clinical findings. , 2003, Diabetes care.

[24]  Lau,et al.  An evaluation of whole blood testing for Helicobacter pylori infection in the Chinese population , 2000, Alimentary pharmacology & therapeutics.

[25]  T. Azuma,et al.  Meta-analysis of the relationship between CagA seropositivity and gastric cancer. , 2004, Gastroenterology.

[26]  H. Straatman,et al.  Evaluation of treatment regimens to cure Helicobacter pylori infection—a meta‐analysis , 1999, Alimentary pharmacology & therapeutics.

[27]  N. Uemura,et al.  Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer in Japan. , 2000, Gastroenterology clinics of North America.

[28]  P. Malfertheiner,et al.  How Do Practicing Clinicians Manage Helicobacter pylori‐Related Gastrointestinal Diseases in Germany? A Survey of Gastroenterologists and Family Practitioners , 1998, Helicobacter.

[29]  D. Graham,et al.  Pretreatment Antibiotic Resistance in Helicobacter pylori Infection: Results of Three Randomized Controlled Studies , 1999, Helicobacter.

[30]  P. Sharma,et al.  Helicobacter pylori and reflux disease , 2003 .

[31]  J. Fraumeni,et al.  Nationwide study of cancer risk among hip replacement patients in Sweden. , 2001, Journal of the National Cancer Institute.

[32]  J. Parsonnet.  When heredity is infectious. , 2000, Gastroenterology.

[33]  M. Inoue,et al.  Effect of early eradication on Helicobacter pylori‐related gastric carcinogenesis in Mongolian gerbils , 2003, Cancer science.

[34]  G. I. Leontiadis,et al.  Non-gastrointestinal tract associations of Helicobacter pylori infection. , 1999, Archives of internal medicine.

[35]  E. Schiff,et al.  Treatment of HCV: approach to difficult cases. , 1997, Clinics in liver disease.

[36]  F. Mégraud,et al.  Which Test to Use to Detect Helicobacter pylori Infection in Patients With Low-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphoma? , 2003, American Journal of Gastroenterology.

[37]  P. Malfertheiner,et al.  Elan study proves symptomatic benefit of Helicobacter pylori eradication in functional dyspepsia(FD) , 2000 .

[38]  J. Hallas,et al.  Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study. , 1999, Gastroenterology.

[39]  D. Graham.  The changing epidemiology of GERD: geography and Helicobacter pylori , 2003, American Journal of Gastroenterology.

[40]  F. Mégraud,et al.  HOW TO TREAT HELICOBACTER PYLORI , 2000 .

[41]  M. Stolte,et al.  Lack of effect of acid suppression therapy on gastric atrophy. , 2000, Gastroenterology.

[42]  A. Helicobacter,et al.  Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts , 2001, Gut.

[43]  J. Gisbert,et al.  Ranitidine bismuth citrate therapy regimens for treatment of Helicobacter pylori infection: a review. , 1999, Helicobacter.

[44]  E. Kuipers,et al.  Role of Helicobacter pylori in the pathogenesis of atrophic gastritis. , 1997, Scandinavian journal of gastroenterology. Supplement.

[45]  C. Hassan,et al.  High eradication rates of Helicobacter pylori with a new sequential treatment , 2003, Alimentary pharmacology & therapeutics.

[46]  S. Lam,et al.  Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection , 1998, Journal of gastroenterology and hepatology.

[47]  D. Graham,et al.  How Do Clinicians Practicing in the U.S. Manage Helicobacter pylori -Related Gastrointestinal Diseases? A Comparison of Primary Care and Specialist Physicians , 1998 .

[48]  A. Blum,et al.  Primary prophylaxis of NSAID-induced gastroduodenal ulcers and dyspepsia in H. pylori (HP)-positive patients: Randomized, double-blind, placebo-controlled treatment of HP infection VS. omeprazole , 2000 .

[49]  P. Sharma,et al.  Review article: Helicobacter pylori and reflux disease. , 2003, Alimentary pharmacology & therapeutics.

[50]  K. Haruma,et al.  Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[51]  M. Franchini,et al.  Helicobacter pylori Infection and Immune Thrombocytopenic Purpura: an Update , 2004, Helicobacter.

[52]  B. Delaney,et al.  Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care , 2000, The Lancet.

[53]  F. Mandelli,et al.  Reversal of Iron Deficiency Anemia after Helicobacter pylori Eradication in Patients with Asymptomatic Gastritis , 1999, Annals of Internal Medicine.

[54]  A. Sonnenberg,et al.  Corpus gastritis is protective against reflux oesophagitis , 1999, Gut.

[55]  Leandro,et al.  The effect of antibiotic resistance on the outcome of three 1‐week triple therapies against Helicobacter pylori , 1999, Alimentary pharmacology & therapeutics.

[56]  D. Kearney,et al.  Iron-Deficiency Anemia and Helicobacter pylori Infection: A Review of the Evidence , 2005, The American Journal of Gastroenterology.

[57]  J. Hatlebakk,et al.  The effect of Helicobacter pylori eradication on gastro‐oesophageal reflux , 1999, Alimentary pharmacology & therapeutics.

[58]  M. Stolte,et al.  Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. , 2000, Gastroenterology.

[59]  D. Graham,et al.  Strategy for treatment of Helicobacter pylori infection in adults. I. Updated indications for test and eradication therapy suggested in 2000. , 2000, Current pharmaceutical design.

[60]  S. Vigneri,et al.  Stool antigen assay (HpSA) is less reliable than urea breath test for post‐treatment diagnosis of Helicobacter pylori infection , 2002, Alimentary pharmacology & therapeutics.

[61]  T. Molina,et al.  Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pyloritreatment , 2001, Gut.

[62]  F. Mégraud,et al.  Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. , 1998, Gastroenterology.

[63]  C. Hawkey,et al.  Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. , 1998, Lancet.

[64]  B. McMahon,et al.  The Relationship among Previous Antimicrobial Use, Antimicrobial Resistance, and Treatment Outcomes for Helicobacter pylori Infections , 2003, Annals of Internal Medicine.

[65]  P. Moayyedi,et al.  How can the current strategies for Helicobacter pylori eradication therapy be improved? , 2003, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[66]  H. Møller,et al.  Use of cimetidine and other peptic ulcer drugs in Denmark 1977-1990 with analysis of the risk of gastric cancer among cimetidine users. , 1992, Gut.

[67]  P. Sipponen,et al.  Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. , 1996, Scandinavian journal of gastroenterology.

[68]  D. Albanes,et al.  Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Helsinki Gastritis Study Group. , 2000, Scandinavian journal of gastroenterology.

[69]  O’connor.  Review article: Helicobacter pylori and gastro‐oesophageal reflux disease—clinical implications and management , 1999, Alimentary pharmacology & therapeutics.

[70]  F. Mégraud,et al.  Comparison of tests for assessment of Helicobacter pylori eradication: results of a multi‐centre study using centralized facility testing , 2000, European journal of gastroenterology & hepatology.

[71]  R. Knill-Jones,et al.  Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. , 1998, The New England journal of medicine.

[72]  M. Carrington,et al.  Interleukin-1 polymorphisms associated with increased risk of gastric cancer , 2000, Nature.

[73]  L. Lundell,et al.  Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. , 1999, Gastroenterology.

[74]  S. Koletzko,et al.  helicobacter pylori Infection in Children: A Consensus Statement , 2000 .

[75]  R. Hunt,et al.  Role of Helicobacter pylori infection in NSAID-associated gastropathy , 2000 .

[76]  C. O'Morain,et al.  Long-term prospective study ofHelicobacter pylori in nonulcer dyspepsia , 2005, Digestive Diseases and Sciences.

[77]  L. Murray,et al.  Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. , 2000, Gastroenterology.

[78]  A. Pilotto,et al.  Treatment of Helicobacter pylori infection in elderly subjects. , 2000, Age and Ageing.

[79]  W. Bao.  Stool Antigen Test for the Diagnosis of Helicobacter Pylori Infection in Children , 2002 .

[80]  J. Cello,et al.  Lack of effect of treatment for Helicobacter pylori on symptoms of nonulcer dyspepsia. , 1999, Archives of internal medicine.

[81]  D. Graham,et al.  Evaluation of gastric mucosal biopsy site and number for identification of Helicobacter pylori or intestinal metaplasia: role of the Sydney System. , 1999, Human pathology.

[82]  X. Calvet,et al.  What is the optimal length of proton pump inhibitor‐based triple therapies for H. pylori? A cost‐effectiveness analysis , 2001, Alimentary pharmacology & therapeutics.

[83]  B. Spiegel,et al.  Dyspepsia management in primary care: a decision analysis of competing strategies. , 2002, Gastroenterology.

[84]  E. Grace,et al.  Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment—Helicobacter pylori positive (CADET-Hp) randomised controlled trial , 2002, BMJ : British Medical Journal.

[85]  J. Gisbert,et al.  Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta‐analysis of eradication of Helicobacter pylori , 2000, Alimentary pharmacology & therapeutics.

[86]  J. Sung,et al.  A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. , 2003, Chinese medical journal.

[87]  G. Sladen,et al.  A TRIAL OF A TEST‐AND‐TREAT STRATEGY FOR HELICOBACTER PYLORI POSITIVE DYSPEPTIC PATIENTS IN GENERAL PRACTICE , 1999, International journal of clinical practice.

[88]  R. Logan,et al.  Testing for Helicobacter pylori infection: validation and diagnostic yield of a near patient test in primary care , 1999, BMJ.

[89]  E. Quigley,et al.  Latin-American Consensus Conference on Helicobacter pylori infection 1 1 A list of delegates to the , 2000 .

[90]  Jacques Ferlay,et al.  Estimates of the worldwide incidence of 25 major cancers in 1990 , 1999, International journal of cancer.

[91]  Talley,et al.  Efficacy of omeprazole in functional dyspepsia: double‐blind, randomized, placebo‐controlled trials (the Bond and Opera studies) , 1998, Alimentary pharmacology & therapeutics.

[92]  R. Spiller,et al.  Does cure of Helicobacter pylori infection induce heartburn , 1998 .

[93]  H. Müller-Hermelink,et al.  Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group. , 2000, Gastroenterology.

[94]  Justin C.Y. Wu,et al.  Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial , 2002, The Lancet.

[95]  E. El-Omar,et al.  Symptomatic benefit 1–3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease , 2000, American Journal of Gastroenterology.

[96]  W. Chey,et al.  Levofloxacin-Based Triple Therapy versus Bismuth-Based Quadruple Therapy for Persistent Helicobacter pylori Infection: A Meta-Analysis , 2006, The American Journal of Gastroenterology.

[97]  M. Baldini.  Idiopathic thrombocytopenic purpura. , 1966, The New England journal of medicine.

[98]  Stolte,et al.  Changes in Helicobacter pylori‐induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro‐oesophageal reflux disease , 1998, Alimentary pharmacology & therapeutics.

[99]  P. Malfertheiner,et al.  Helicobacter pylori Eradication Has the Potential to Prevent Gastric Cancer: A State-of-the-Art Critique , 2005, The American Journal of Gastroenterology.

[100]  D. Forman.  Helicobacter pylori and gastric cancer: the risk is real , 2000 .

[101]  Y. Ikeda,et al.  Is Eradication Therapy Useful as the First Line of Treatment in Helicobacter pylori-Positive Idiopathic Thrombocytopenic Purpura? Analysis of 207 Eradicated Chronic ITP Cases in Japan , 2005, International journal of hematology.

[102]  R. Hunt,et al.  Guidelines for the management of Helicobacter pylori infection , 1998, American Journal of Gastroenterology.

[103]  F. Mégraud,et al.  Second‐line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies , 2003, Alimentary pharmacology & therapeutics.

[104]  C. Dupont,et al.  High Levels of Resistance to Metronidazole and Clarithromycin in Helicobacter pylori Strains in Children , 2001, Journal of Clinical Microbiology.

[105]  A B West,et al.  An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. , 1998, Cancer research.

[106]  L. Marzio,et al.  Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. , 2000, Alimentary pharmacology & therapeutics.

[107]  J. Danesh,et al.  Helicobacter pylori infection and early onset myocardial infarction: case-control and sibling pairs study , 1999, BMJ.

[108]  D. Graham,et al.  Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective? , 1999, American Journal of Gastroenterology.

[109]  J. Gisbert,et al.  Diagnosis of Helicobacter pylori infection by stool antigen determination: a systematic review , 2001, American Journal of Gastroenterology.

[110]  P. Malfertheiner,et al.  Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease — results from a randomized trial programme , 2002, Alimentary pharmacology & therapeutics.

[111]  J. Gisbert,et al.  Systematic review and meta‐analysis: levofloxacin‐based rescue regimens after Helicobacter pylori treatment failure , 2006, Alimentary pharmacology & therapeutics.

[112]  Robert G. Woodland,et al.  Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents--an evidence-based evaluation. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[113]  M. Stolte,et al.  Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series , 2003, Gut.

[114]  P. Boffetta,et al.  Cancer in developing countries , 1994, CA: a cancer journal for clinicians.

[115]  J. Mason,et al.  Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. , 2000, BMJ.

[116]  F. Chan,et al.  Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. , 2001, The New England journal of medicine.

[117]  L. Tryggvadottir,et al.  Genetic epidemiologic aspects of gastric cancer in Iceland. , 2002, Journal of the American College of Surgeons.

[118]  P. Malfertheiner,et al.  Helicobacter pylori infection and gastro-oesophageal reflux disease: coincidence or association? , 2000, Bailliere's best practice & research. Clinical gastroenterology.

[119]  P. Malfertheiner,et al.  Effect of omeprazole on Helicobacter pylori urease activity in vivo. , 1996, European journal of gastroenterology & hepatology.

[120]  D. Forman,et al.  Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus , 2003 .

[121]  E. Kuipers,et al.  Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. , 1996, The New England journal of medicine.

[122]  S. Koletzko,et al.  Helicobacter pylori infection in children: a consensus statement. European Paediatric Task Force on Helicobacter pylori. , 2000, Journal of pediatric gastroenterology and nutrition.

[123]  E. El-Omar,et al.  Helicobacter pylori infection and chronic gastric acid hyposecretion. , 1997, Gastroenterology.

[124]  M. Färkkilä,et al.  Diagnosis of Helicobacter pylori Infection in Patients with Atrophic Gastritis: Comparison of Histology, 13C-Urea Breath Test, and Serology , 2000, Scandinavian journal of gastroenterology.

[125]  J. Dent,et al.  Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. , 2000, Gastroenterology.

[126]  J. Holton,et al.  Review article:invasive and non-invasive tests for Helicobacter pylori infection. , 2000, Alimentary pharmacology & therapeutics.

[127]  N. Okabe,et al.  Association of Helicobacter pylori infection with atrophic gastritis and intestinal metaplasia , 2000, Journal of gastroenterology and hepatology.

[128]  Brendan Delaney,et al.  Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia , 2000, BMJ : British Medical Journal.

[129]  C. Ciacci,et al.  Helicobacter pylori impairs iron absorption in infected individuals. , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[130]  N. Vakil,et al.  The cost-effectiveness of diagnostic testing strategies for Helicobacter pylori , 2000, American Journal of Gastroenterology.

[131]  R. Hunt,et al.  Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis , 2002, The Lancet.

[132]  R. Marmo,et al.  Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[133]  F. Perri,et al.  Helicobacter pylori antigen stool test and 13C-urea breath test in patients after eradication treatments , 2002, American Journal of Gastroenterology.

[134]  Y. Yamaoka,et al.  Early events in proton pump inhibitor‐associated exacerbation of corpus gastritis , 2003, Alimentary pharmacology & therapeutics.

[135]  A. Verbeek,et al.  Evaluation of Commercially AvailableHelicobacter pylori Serology Kits: a Review , 1998, Journal of Clinical Microbiology.

[136]  P. Malfertheiner.  European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection. The Maasticht 2-2000 Consensus Report , 2002 .

[137]  C. Ricci,et al.  Invasive and non‐invasive tests for Helicobacter pylori infection , 2000, Alimentary pharmacology & therapeutics.

[138]  J. Mason,et al.  Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial , 2000, The Lancet.

[139]  A. Zullo,et al.  Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure , 2004, Alimentary pharmacology & therapeutics.

[140]  P. Malfertheiner,et al.  Current concepts in the management of Helicobacter pylori infection—The Maastricht 2‐2000 Consensus Report , 2002, Alimentary pharmacology & therapeutics.

[141]  N. Talley,et al.  Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up , 1999 .

[142]  Á. Lanas,et al.  Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study , 1998, The Lancet.

[143]  Savarino,et al.  Effect of gastric acid suppression on 13C‐urea breath test: comparison of ranitidine with omeprazole , 2000, Alimentary pharmacology & therapeutics.

[144]  M. Stolte,et al.  Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. , 1997, Journal of the National Cancer Institute.

[145]  L. Murray,et al.  Omeprazole and accelerated onset of atrophic gastritis. , 2000, Gastroenterology.

[146]  J. Danesh.  Helicobacter pylori and gastric cancer: time for mega-trials? , 1999, British Journal of Cancer.

[147]  Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting , 1999 .

[148]  L. Irwig,et al.  Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. , 1996, The American journal of gastroenterology.

[149]  L. Laine,et al.  Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies , 2002, American Journal of Gastroenterology.

[150]  A. Axon.  Eradication of Helicobacter pylori. , 1996, Scandinavian journal of gastroenterology. Supplement.

[151]  M. Poljak,et al.  Two‐ to four‐year histological follow‐up of gastric mucosa after Helicobacter pylori eradication , 1999, The Journal of pathology.

[152]  S. Leung,et al.  Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. , 2004, JAMA.

[153]  E. Kuipers,et al.  EVect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy , 2000 .

[154]  J. Wood,et al.  One‐week clarithromycin triple therapy regimens for eradication of Helicobacter pylori , 1998 .

[155]  J. Kleibeuker,et al.  The influence of Helicobacter pylori on oesophageal acid exposure in GERD during acid suppressive therapy , 1999, Alimentary pharmacology & therapeutics.

[156]  C. O'Morain,et al.  One week triple therapy for Helicobacter pylori: a multicentre comparative study , 1997, Gut.

[157]  P. Correa,et al.  Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. , 1992, Cancer research.

[158]  A. Blum,et al.  Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. , 1998, The New England journal of medicine.

[159]  Douglas K Owens,et al.  Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials , 1996, The Lancet.

[160]  Annmarie Touborg Lassen,et al.  Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial , 2000, The Lancet.

[161]  P. Unge.  Antimicrobial treatment of H. pylori infection--a pooled efficacy analysis of eradication therapies. , 2003, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement.

[162]  F. Mégraud.  Update on therapeutic options for Helicobacter pylori-related diseases , 2005, Current infectious disease reports.

[163]  Joseph K McLaughlin,et al.  Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. , 2004, Journal of the National Cancer Institute.

[164]  F. Perna,et al.  Effect of Proton Pump Inhibitors and Antacid Therapy on 13C Urea Breath Tests and Stool Test for Helicobacter Pylori Infection , 2004, American Journal of Gastroenterology.

[165]  J. Wood,et al.  Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. , 1998, Alimentary pharmacology & therapeutics.

[166]  L. Fischbach,et al.  Meta‐analysis: the efficacy, adverse events, and adherence related to first‐line anti‐Helicobacter pylori quadruple therapies , 2004, Alimentary pharmacology & therapeutics.

[167]  E. Negri,et al.  Risk indicators of organic diseases in uninvestigated dyspepsia: a one-week survey in 246 Italian endoscopy units. , 1999, European journal of gastroenterology & hepatology.

[168]  A. Gasbarrini,et al.  Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori , 1998, The Lancet.

[169]  M. Blaser,et al.  Helicobacter pylori factors associated with disease. , 1999, Gastroenterology.

[170]  D. Graham,et al.  Antibiotic resistance in Helicobacter pylori : Implications for therapy , 1998 .

[171]  Kamada,et al.  High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis , 2000, Alimentary pharmacology & therapeutics.

[172]  F. Chan,et al.  How does Helicobacter pylori infection interact with non-steroidal anti-inflammatory drugs? , 2000, Bailliere's best practice & research. Clinical gastroenterology.

[173]  F. Mégraud,et al.  Which test to use to detect Helicobacter pylori infection in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma? , 2003 .

[174]  P. Apfalter,et al.  Two Enzyme Immunoassays and PCR for Detection ofHelicobacter pylori in Stool Specimens from Pediatric Patients before and after Eradication Therapy , 2000, Journal of Clinical Microbiology.

[175]  M. Franchini,et al.  Helicobacter pylori-associated immune thrombocytopenia , 2006, Platelets.

[176]  R. Hunt,et al.  Canadian Helicobacter Study Group Consensus Conference on the Approach to Helicobacter pylori Infection in Children and Adolescents. , 1999, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[177]  J. Gisbert,et al.  Meta‐analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users , 2005, Alimentary pharmacology & therapeutics.

[178]  A. Blum,et al.  Short course acid suppressive treatment for patients with functional dyspepsia: results depend onHelicobacter pyloristatus , 2000, Gut.

[179]  J. Gisbert,et al.  Stool Antigen Test for the Diagnosis of Helicobacter pylori Infection: a Systematic Review , 2004, Helicobacter.

[180]  W. Chey,et al.  Noninvasive Helicobacter pylori testing for the "test-and-treat" strategy: a decision analysis to assess the effect of past infection on test choice. , 2001, Archives of internal medicine.

[181]  F. Mégraud,et al.  Review article: the treatment of refractory Helicobacter pylori infection , 2003, Alimentary pharmacology & therapeutics.

[182]  P. Malfertheiner,et al.  Diagnosis of Helicobacter pylori infection with a new non-in vasive antigen-based assay , 1999, The Lancet.

[183]  D. Forman.  Lessons from Ongoing Intervention Studies , 1998 .

[184]  M. Gail,et al.  Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. , 2001, Journal of the National Cancer Institute.

[185]  R. P. Blankfield,et al.  Helicobacter pylori infection and the development of gastric cancer. , 2001, The New England journal of medicine.

[186]  J. Fraumeni,et al.  Red meat, family history, and increased risk of gastric cancer with microsatellite instability. , 2001, Cancer research.

[187]  E. Kuipers,et al.  GI SNAPSHOT , 2003, Gut.

[188]  R. Hunt,et al.  Canadian Helicobacter pylori Consensus Conference update: infections in adults. Canadian Helicobacter Study Group. , 1999, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[189]  J. Gisbert,et al.  Review article: 13C‐urea breath test in the diagnosis of Helicobacter pylori infection – a critical review , 2004, Alimentary pharmacology & therapeutics.

[190]  M. Asaka,et al.  Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura , 2005, Annals of Hematology.

[191]  N. Vakil,et al.  Blood, urine, stool, breath, money, andHelicobacter pylori , 2001, Gut.

[192]  G. Porro,et al.  Omeprazole and sucralfate in the treatment of NSAID‐induced gastric and duodenal ulcer , 1998, Alimentary pharmacology & therapeutics.

[193]  M. Gail,et al.  Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. , 2000, Journal of the National Cancer Institute.

[194]  F. Mégraud.  H pylori antibiotic resistance: prevalence, importance, and advances in testing , 2004, Gut.

[195]  Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. , 2002, The New England journal of medicine.

[196]  L. Bravo,et al.  Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection , 1999, American Journal of Gastroenterology.